Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diltiazem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S known ✓ | Q13698 | 11/20 | 0.83 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.83 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.83 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.83 |
| ▸ | TSHR | P16473 | 2/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.83 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.83 |
| ▸ | HRH2 | P25021 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | SCN1A | P35498 | 1/20 | 0.83 |
| ▸ | SCN4A | P35499 | 1/20 | 0.83 |
| ▸ | HTT | P42858 | 1/20 | 0.83 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.83 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.83 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.83 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diltiazem SCHEMBL721521 | 1.00 | CACNA1S (0.83) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL29509685 | 1.00 | CACNA1S (0.83) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL12492950 | 0.96 | CACNA1S (0.77) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL7442170 | 0.93 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL9791428 | 0.92 | CACNA1S (0.88) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL7861010 | 0.91 | CACNA1S (0.96) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL614334 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL3468378 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL4886734 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL676914 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-5314506-A | Homogeneous mixing prior to nucleation | MERCK & CO., INC. (US) | 1994-05-24 | — | — | US | claimed |
| EP-0309051-B1 | CONTROLLED POROSITY OSMOTIC PUMP | MERCK & CO. INC. (US) | 1992-03-11 | — | — | EP | claimed |
| US-4886668-A | CONTROLLED RELEASE OF DILTIAZEM L-MALEATE | MERCK & CO., INC. (US) | 1989-12-12 | — | — | US | claimed |
| US-4880631-A | DILTIAZEM MALATE WITH SODIUM BITARTRATE BUFFER CORE, POLYMER | MERCK & CO., INC. (US) | 1989-11-14 | — | — | US | claimed |
| EP-0309051-A1 | Controlled porosity osmotic pump | MERCK & CO. INC. (US) | 1989-03-29 | — | — | EP | claimed |
| JP-1128927-A | — | — | None | — | — | JP | disclosed |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | ImMutriX Therapeutics, Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-3689357-B1 | COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME | ADVANCED REGEN MEDICAL TECH LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024215303-A1 | NOVEL DRUG DELIVERY SYSTEMS AND METHODS OF MAKING AND USING SAME | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4445915-A2 | CELL FREE COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME | Advanced Regen Medical Technologies, LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240294909-A1 | AGENTS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF HYPOXIA AND ISCHEMIA-RELATED DISORDERS | MERAND PHARMACEUTICALS INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-4886668-A | CONTROLLED RELEASE OF DILTIAZEM L-MALEATE | MERCK & CO., INC. (US) | 1989-12-12 | — | — | US | disclosed |
| US-4886668-A | CONTROLLED RELEASE OF DILTIAZEM L-MALEATE | MERCK & CO., INC. (US) | 1989-12-12 | — | — | US | disclosed |
| US-4880631-A | DILTIAZEM MALATE WITH SODIUM BITARTRATE BUFFER CORE, POLYMER | MERCK & CO., INC. (US) | 1989-11-14 | — | — | US | disclosed |
| US-4880631-A | DILTIAZEM MALATE WITH SODIUM BITARTRATE BUFFER CORE, POLYMER | MERCK & CO., INC. (US) | 1989-11-14 | — | — | US | disclosed |
| JP-H01128927-A | CONTROLLED POROUS OSMOTIC PUMP | MERCK & CO INC | 1989-05-22 | — | — | JP | disclosed |
| EP-0309051-A1 | Controlled porosity osmotic pump | MERCK & CO. INC. (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0309051-A1 | Controlled porosity osmotic pump | MERCK & CO. INC. (US) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | CACNA1S 308/4885CACNA1F 353/4885CACNA1D 269/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | CACNA1S 20/4885CACNA1F 2/4885CACNA1D 15/4885 |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | TEK, FLT4, PGF | CACNA1S 4710/4885CACNA1F 4572/4885CACNA1D 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.